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The original version of this article unfortunately con-
tained a mistake. The “Acknowledgement” section was 
incorrect and included Dr. Catherine Tamalet. Dr. Cath-
erine Tamalet should not be included in the “Acknowl-
edgement” section for the following reasons:
Dr. Catherine Tamalet requests to be withdrawn from 
the “Acknowledgements” section in this article, on the 
following grounds: (a) No permission was asked of her 
to be acknowledged. (b) She did not read the manu-
script before its publication. (c) The method depicted in 
the “Methods” section to quantify HIV DNA [“Generic 
HIV assay (Biocentric, Bandol, Provence) with a cut off 
of 20 copies/million of peripheral blood mononuclear 
cells (PBMC)”] is not the method employed in her lab-
oratory. Dr. Tamaret routinely employs an “in-House” 
method with a cut-off of 20 copies. Dr. Thamalet was in 
the acknowledgement for fruitful discussion and not for 
her participation to the study.
Dr. Catherine Tamalet has been removed from the 
original article [1].
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